y Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis

doi:10.1038/s41598-020-59470-w

	y Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis
	Wang, Fangzheng 1,2,3,4; Jiang, Chuner 1,5,6; Wang, Lai 1,2,3,4; Yan, Fengqin 1,2,3,4; Sun, Quanquan 1,2,3,4; Ye, Zhimin 1,2,3,4; Liu, Tongxin 1,2,3,4; Fu, Zhenfu 1,2,3,4; Jiang, Yangming 7
刊名	SCIENTIFIC REPORTS
	2020-02-12
卷号	10
ISSN号	2045-2322
DOI	10.1038/s41598-020-59470-w
通讯作者	Wang, Fangzheng(wangfz@zjcc.org.cn) ; Jiang, Yangming(jym_wm@126.com)
英文摘要	Neoadjuvant chemotherapy (NAC) combined with intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy (CC) will be the new standard treatment for locoregionally advanced nasopharyngeal carcinoma (NPC) patients. However, many patients fail to receive CC for multiple reasons. We aimed to investigate long-term survival outcomes and toxicities in these patients with NPC treated with additional NAC plus concurrent chemoradiotherapy (CCRT) or IMRT alone. In total, 1,378 previously untreated, newly diagnosed locoregionally advanced NPC patients receiving NAC plus IMRT with or without CC were retrospectively reviewed. We used a propensity score-matched (PSM) method with 1:1 matching to identify paired patients according to various covariates. Survival outcomes and toxicities were compared between the two groups. In total, 288 pairs were identified. With a median follow-up of 86 (range: 8-110) months, the estimated 5-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival (PFS), and overall survival rates in patients treated with NAC plus CCRT vs. NAC plus IMRT alone were 96.1% vs. 94.7% (P = 0.201), 93.7% vs. 89.8% (P = 0.129), 91.3% vs. 85.1% (P = 0.024), and 93.0% vs. 90.6% (P = 0.362), respectively. Multivariate analysis showed that CC omission was a prognostic factor for worse PFS. In a subgroup analysis, PFS did not differ significantly between two groups of female patients or aged <60 years or stage T1-2 or stage N0-1 disease. However, fewer acute complications were observed in the NAC plus IMRT alone group. NAC with IMRT alone confers similar survival rates and less acute toxicities. Specifically, NAC plus IMRT alone may be enough for female patients <60 years with stage T1-2 or stage N0-1. However, a prospective randomised trial is needed to validate these results.
资助项目	Medical Science Foundation of Zhejiang Health Bureau[2020KY084] ; Medical Science Foundation of Zhejiang Health Bureau[2019KY041] ; Medical Science Foundation of Zhejiang Health Bureau[2013KYB033] ; Medical Science Foundation of Zhejiang Health Bureau[2009B026] ; Medical Science Foundation of Zhejiang Health Bureau[2006A016] ; Medical Science Foundation of Zhejiang Health Bureau[2005B012] ; Medical Science Foundation of Zhejiang Health Bureau[2004B014] ; National Natural Science Foundation of China[81502646] ; National Natural Science Foundation of China[81502647]
WOS关键词	PROPENSITY SCORE METHODS ; RANDOMIZED PHASE-II ; INDUCTION CHEMOTHERAPY ; ADJUVANT CHEMOTHERAPY ; CISPLATIN-RADIOTHERAPY ; ENDEMIC AREA ; CHEMORADIOTHERAPY ; TRIAL ; SURVIVAL ; METAANALYSIS
WOS研究方向	Science & Technology - Other Topics
语种	英语
出版者	NATURE PUBLISHING GROUP
WOS记录号	WOS:000562873200003
资助机构	Medical Science Foundation of Zhejiang Health Bureau ; National Natural Science Foundation of China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/102881]
专题	中国科学院合肥物质科学研究院
通讯作者	Wang, Fangzheng; Jiang, Yangming
作者单位	1.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou 310022, Zhejiang, Peoples R China 2.Univ Chinese Acad Sci, Dept Radiat Oncol, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 3.Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou 310022, Zhejiang, Peoples R China 4.Key Lab Radiat Oncol Zhejiang Prov, Hangzhou 310022, Zhejiang, Peoples R China 5.Univ Chinese Acad Sci, Dept Breast Tumor Surg, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 6.Zhejiang Canc Hosp, Dept Breast Tumor Surg, Hangzhou 310022, Zhejiang, Peoples R China 7.Chinese Acad Sci, Dept Didital Earth, Inst Remote Sensing & Digital Earth, Beijing 100101, Peoples R China
推荐引用方式 GB/T 7714	Wang, Fangzheng,Jiang, Chuner,Wang, Lai,et al. y Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis[J]. SCIENTIFIC REPORTS,2020,10.
APA	Wang, Fangzheng.,Jiang, Chuner.,Wang, Lai.,Yan, Fengqin.,Sun, Quanquan.,...&Jiang, Yangming.(2020).y Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis.SCIENTIFIC REPORTS,10.
MLA	Wang, Fangzheng,et al."y Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis".SCIENTIFIC REPORTS 10(2020).